"But if you look at the total size of the deal, that's going to be a tiny fraction," one of the lawyers said. It may also be harder to find buyers for those drugs given the consolidation already seen in the generics sector, they said. The U.S. Federal Trade Commission requires buyers for proposed divestitures before it will approve a deal. Teva said it has identified asset sales needed for the deal to pass muster with U.S. and UK antitrust regulators, and that the number was less than what had been anticipated in a combination with Mylan. CULTURAL FIT Teva said it had approached Allergan a year ago but did not generate interest. It then went after Mylan, which repeatedly rebuffed its offers, and only turned its attention back to Allergan earlier this month. In June 2014, Vigodman hired Sigurdur Olafsson, former head of Actavis's generic drug business, to fill a similar role at Teva.